Monday, November 29, 2021

‘Mix-and-match’ for Pfizer, AstraZeneca jabs still being studied, says Khairy

He says the issue has been raised with the Covid-19 Vaccine Supply Access Guarantee Special Committee but no final decision has been made.

Other News

The government is still studying and considering the mix-and-match method for the Pfizer-BioNTech and AstraZeneca Covid-19 vaccines to complete the two-dose vaccination regime.

National Covid-19 Immunisation Programme coordinating minister Khairy Jamaluddin said the issue had been tabled at the Covid-19 Vaccine Supply Access Guarantee Special Committee (JKJAV) meeting two weeks ago but that no decision had been finalised to date.

“The mixing of vaccine doses is still under study and we tabled it at JKJAV last week but it has not been finalised by our technical committee,” he told reporters after visiting the vaccination centre at the Gong Badak Indoor Stadium at the state sports complex in Kuala Nerus today.

Khairy, in a webinar session hosted by the Oxford and Cambridge Society of Malaysia yesterday, was reported as referring to real-world data from Germany on heterological vaccinations using AstraZeneca as the first dose and Pfizer as the second, which had been proven to boost the neutralisation of antibodies and boost effectiveness against variants.

Khairy, who is science, technology and innovation minister, also said Terengganu would receive over 200,000 doses of Covid-19 vaccine from next month which would help the state administer 12,000 doses a day.

“We will definitely increase the delivery of vaccines to Terengganu especially from July. We will discuss after this but we are expecting to send more than 200,000 doses,” he said.

State health department director Dr Nor Azimi Yunus previously said 5,380 Covid-19 shots are being dispensed daily to the people of Terengganu at 14 PPVs statewide.

Meanwhile, Khairy said discussions are being held on sending mobile outreach teams to vaccinate residents on Pulau Redang and Pulau Perhentian.

Follow us on Telegram for the latest updates:

Subscribe to our newsletter

To be updated with all the latest news and analyses.

Related Articles